Zenith Drugs (NSE:ZENITHDRUG) Total Receivables: ₹863 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:ZENITHDRUG Zenith Drugs Ltd NSE:ZENITHDRUG
36 GF Score
Price ₹51.00
! 8 Warning Signs
View Full Analysis

What is Zenith Drugs Total Receivables?

Zenith Drugs NSE:ZENITHDRUG +1.80% 36 Total Receivables is ₹863 Mil as of Mar. 2026. GuruFocus rates NSE:ZENITHDRUG with a GF Score™ of 36/100. The stock has 8 warning signs investors should review.

Zenith Drugs's Total Receivables for the quarter that ended in Mar. 2026 was ₹863 Mil.

Zenith Drugs Total Receivables Historical Data

* Premium members only.

The historical data trend for Zenith Drugs's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zenith Drugs Total Receivables Chart

Zenith Drugs Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Receivables
Get a 7-Day Free Trial 321.36 496.32 676.32 607.95 862.81

Zenith Drugs Semi-Annual Data
Mar21 Mar22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Total Receivables Get a 7-Day Free Trial Premium Member Only 676.32 0.00 607.95 733.65 862.81
NSE:ZENITHDRUG
36GF Score
Zenith Drugs Ltd NSE:ZENITHDRUG
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zenith Drugs Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of ₹863 Mil mean?
Zenith Drugs (NSE:ZENITHDRUG) has a Total Receivables of ₹863 Mil as of Mar. 2026. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Zenith Drugs and its competitors.
Is Zenith Drugs' Total Receivables too high?
Zenith Drugs' current Total Receivables is ₹863 Mil. Overall, Zenith Drugs has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does Zenith Drugs' Total Receivables compare to ZTS and UTHR?
Zenith Drugs' Total Receivables of ₹863 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Drug Manufacturers company?
A good Total Receivables depends on the Drug Manufacturers industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Zenith Drugs and its competitors. Zenith Drugs's current Total Receivables is ₹863 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zenith Drugs stock overvalued right now?
Zenith Drugs (NSE:ZENITHDRUG) has a current Total Receivables of ₹863 Mil. The current Total Receivables is ₹863 Mil. Zenith Drugs' overall GF Score™ is 36/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Zenith Drugs (NSE:ZENITHDRUG), the current Total Receivables is ₹863 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Zenith Drugs Business Description

Address K. No. 72/5, Village Muradpura, Depalpur, Indore, MP, IND, 453001
Zenith Drugs Ltd is a pharmaceutical manufacturing and trading company. It offers a wide range of formulations in various forms such as ORS Powder, Liquid Orals, Ointments, Liquid Externals, Creams, Gels, Capsules, and Tablets. It is also into Generic Medicines.
36GF Score

Get the complete analysis for NSE:ZENITHDRUG

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹51.00
Price